Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.41 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14813509 | 1.00 | CA1 (0.45) | CA1CA2ZDHHC7SLC1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL1068300 | 1.00 | CA1 (0.45) | CA1CA2ZDHHC7SLC1A1GRIK1 | |
| SCHEMBL628809 | 0.98 | — | — | |
| SCHEMBL628810 | 0.98 | — | — | |
| SCHEMBL9068327 | 0.98 | — | — | |
| SCHEMBL10402326 | 0.88 | CA1 (0.40) | CA1CA2ZDHHC7SLC1A1GRIK1 | |
| Hydrochloric Acid SCHEMBL186089 | 0.87 | CA1 (0.57) | CA1CA2ZDHHC7SLC1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL5192659 | 0.87 | CA1 (0.57) | CA1CA2ZDHHC7SLC1A1SLC1A3 | |
| Hydrochloric Acid SCHEMBL186088 | 0.87 | CA1 (0.57) | CA1CA2ZDHHC7SLC1A1SLC1A3 | |
| SCHEMBL11776470 | 0.85 | SMN1; SMN2 (0.42) | CA1CA2ZDHHC7SLC1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306633-B | Beta-form3Method for synthesizing amino acid derivatives | 深圳市第二人民医院(深圳市转化医学研究院) | 2025-04-25 | — | — | CN | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| WO-2025070711-A1 | AFLATOXIN PRODUCTION-INHIBITING BACTERIUM, AFLATOXIN PRODUCTION INHIBITOR PRODUCED BY AFLATOXIN PRODUCTION-INHIBITING BACTERIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR CONTROLLING AFLATOXIN CONTAMINATION USING SAID BACTERIUM OR SAID INHIBITOR | 学校法人帝京大学 | 2025-04-03 | — | — | WO | disclosed |
| CN-119306633-A | Beta-form3Method for synthesizing amino acid derivatives | 深圳市第二人民医院(深圳市转化医学研究院) | 2025-01-14 | — | — | CN | disclosed |
| CN-116496178-B | Compound with syringic acid and amino acid structural fragments and synthesis and application thereof | 合肥工业大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-113402436-B | Tertiary amino acid derivative, preparation method and application thereof | 安徽农业大学 | 2024-07-12 | — | — | CN | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| CN-111788191-B | 1- (Piperidinylcarbonylmethyl) -2-oxopiperazine derivatives for the treatment of cancer | 英夕亚生物科技股份公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0373549-A2 | Amino acid derivatives with enzyme-inhibiting properties, process to synthetise them, composition containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-20 | — | — | EP | disclosed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0370383-A2 | Renin-inhibiting dipeptides, process to make them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| EP-0370382-A2 | Urea dipeptide derivatives with a renin-inhibiting activity, process to produce them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0132732-B1 | HOMOLOGUES FROM APROTININE WHOSE LYS 15 AMINO ACID IS SUBSTITUTED BY OTHER AMINO ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1988-06-08 | — | — | EP | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4595674-A | Pharmaceuticals | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-17 | — | — | US | disclosed |
| EP-0132732-A2 | Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments | BAYER AG (DE) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | CA2 1597/4885DPP4 920/4885HDAC7 837/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | CA2 1597/4885DPP4 920/4885HDAC7 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.